ConvaTec Group Beheer

Beheer criteriumcontroles 3/4

De CEO ConvaTec Group is Karim Bitar, benoemd in Sep2019, heeft een ambtstermijn van 5.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 5.44M, bestaande uit 22% salaris en 78% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.16% van de aandelen van het bedrijf, ter waarde £ 7.73M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.2 jaar en 4.3 jaar.

Belangrijke informatie

Karim Bitar

Algemeen directeur

US$5.4m

Totale compensatie

Percentage CEO-salaris	22.0%
Dienstverband CEO	5.2yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	4.2yrs
Gemiddelde ambtstermijn bestuur	4.3yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Karim Bitar's beloning veranderd ten opzichte van ConvaTec Group's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	US$153m
Mar 31 2024	n/a	n/a	US$142m
Dec 31 2023	US$5m	US$1m	US$130m
Sep 30 2023	n/a	n/a	US$100m
Jun 30 2023	n/a	n/a	US$70m
Mar 31 2023	n/a	n/a	US$67m
Dec 31 2022	US$5m	US$1m	US$63m
Sep 30 2022	n/a	n/a	US$72m
Jun 30 2022	n/a	n/a	US$80m
Mar 31 2022	n/a	n/a	US$99m
Dec 31 2021	US$5m	US$1m	US$118m
Sep 30 2021	n/a	n/a	US$128m
Jun 30 2021	n/a	n/a	US$139m
Mar 31 2021	n/a	n/a	US$126m
Dec 31 2020	US$4m	US$1m	US$113m
Sep 30 2020	n/a	n/a	US$68m
Jun 30 2020	n/a	n/a	US$24m
Mar 31 2020	n/a	n/a	US$17m
Dec 31 2019	US$9m	US$294k	US$10m

Compensatie versus markt: De totale vergoeding ($USD 5.44M ) Karim } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de UK markt ($USD 3.27M ).

Compensatie versus inkomsten: De vergoeding van Karim is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Karim Bitar (59 yo)

5.2yrs

Tenure

US$5,435,794

Compensatie

Mr. Karim Bitar serves as Chief Executive Officer and Director at Convatec Group Plc since September 30, 2019. Mr. Bitar served as the Chief Executive Officer of Genus plc from September 30, 2011 to Septem...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Karim Bitar	CEO & Director	5.2yrs	US$5.44m	0.16% £ 7.7m
Jonathan Mason	Group CFO & Director	2.7yrs	US$2.02m	0.0024% £ 118.2k
John Haller	Executive VP and Chief Quality & Operations Officer	2.8yrs	geen gegevens	geen gegevens
Divakar Ramakrishnan	Executive VP	4.8yrs	geen gegevens	geen gegevens
Kate Postans	Vice President of Investor Relations & Corporate Communications	no data	geen gegevens	geen gegevens
Evelyn Douglas	Executive VP	3.6yrs	geen gegevens	geen gegevens
Moyra Withycombe	Interim Chief People Officer	no data	geen gegevens	geen gegevens
Kjersti Grimsrud	President & COO of Infusion Care	6.8yrs	geen gegevens	geen gegevens
David Shepherd	President & COO of Global Advanced Wound Care	4.8yrs	geen gegevens	geen gegevens
Seth Segel	President and COO of Continence Care & Home Services Group	4.8yrs	geen gegevens	geen gegevens
Bruno Pinheiro	President & COO of Ostomy Care	3.2yrs	geen gegevens	geen gegevens
Anne Belcher	President & COO of Global Emerging Markets	2.8yrs	geen gegevens	geen gegevens

4.2yrs

Gemiddelde duur

59.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van CTECL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Karim Bitar	CEO & Director	5.2yrs	US$5.44m	0.16% £ 7.7m
Jonathan Mason	Group CFO & Director	2.7yrs	US$2.02m	0.0024% £ 118.2k
John David McAdam	Independent Chairman	5.2yrs	US$427.06k	0.0011% £ 54.7k
Heather Mason	Independent Non-Executive Director	4.3yrs	US$103.26k	0.00049% £ 23.7k
Kimberly Lody	Independent Non-Executive Director	2.8yrs	US$104.53k	0.00049% £ 23.7k
Margaret Ewing	Senior Independent Director	7.3yrs	US$154.25k	0.00049% £ 23.7k
Brian May	Independent Non-Executive Director	4.7yrs	US$124.93k	0.0012% £ 59.1k
Sharon O'Keefe	Independent Non-Executive Director	2.7yrs	US$117.28k	0.00016% £ 7.7k
Constantin-Cassios Coussios	Independent Non-Executive Director	4.2yrs	US$99.44k	0.0011% £ 55.2k

4.3yrs

Gemiddelde duur

60yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van CTECL wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.3 jaar).

ConvaTec Group Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

ConvaTec Group PLC, Annual General Meeting, May 16, 2024

Group CFO & Director recently bought UK£64k worth of stock

High number of new directors

High number of new directors

Convatec Group plc Announces Board Changes

ConvaTec Group Plc Appoints Constantin Coussios as Member of Remuneration Committee and Nomination Committee

Recent updates

ConvaTec Group PLC Provides Revenue Guidance for the Full Year 2024

Upcoming dividend of UK£0.035 per share

Convatec Launches New Esteem Body with Leak Defense

Now 21% overvalued after recent price rise

ConvaTec Group plc Recommends Final Dividend, Payable on 23 May 2024

Full year 2023 earnings released: EPS: US$0.064 (vs US$0.031 in FY 2022)

ConvaTec Group PLC, Annual General Meeting, May 16, 2024

ConvaTec Group PLC to Report First Half, 2024 Results on Jul 30, 2024

ConvaTec Group PLC Revises Earnings Guidance for the Year 2023

ConvaTec Group PLC to Report Fiscal Year 2023 Results on Mar 06, 2024

An unknown buyer acquired an unknown minority stake in ConvaTec Group PLC from Novo Holdings A/S.

Upcoming dividend of UK£0.014 per share at 2.1% yield

ConvaTec Group plc Declares Interim Dividend for the Six Months Ended June 30, 2023

New major risk - Financial position

First half 2023 earnings released: EPS: US$0.027 (vs US$0.024 in 1H 2022)

Now 21% undervalued after recent price drop

ConvaTec Group PLC Provides Revenue Guidance for the Year 2023

Upcoming dividend of UK£0.037 per share at 2.2% yield

Full year 2022 earnings released: EPS: US$0.031 (vs US$0.059 in FY 2021)

Group CFO & Director recently bought UK£64k worth of stock

ConvaTec Group Plc to Report Fiscal Year 2022 Results on Mar 09, 2023

High number of new directors

ConvaTec Group plc Provides Revenue Guidance for the Full Year of 2022

ConvaTec Group Plc(LSE:CTEC) dropped from FTSE 250 Index

Upcoming dividend of UK£0.014 per share

First half 2022 earnings released

Convatec Group plc Declares an Unchanged Interim Dividend for First Half of 2022

Now 21% undervalued

ConvaTec Group Plc Provides Earnings Guidance for the Full Year 2022

High number of new directors

Upcoming dividend of UK£0.032 per share

Investor sentiment improved over the past week

Convatec Group plc Proposes Final Dividend for Year 2021, Payable on May 19, 2022

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Convatec Group plc Announces Board Changes

ConvaTec Group Plc (LSE:CTEC) agreed to acquire Triad Life Sciences, Inc. for $450 million.

ConvaTec Group Plc Appoints Constantin Coussios as Member of Remuneration Committee and Nomination Committee

Upcoming dividend of UK£0.012 per share

First half 2021 earnings released: EPS US$0.043 (vs US$0.03 in 1H 2020)

Company Secretary has left the company

ConvaTec Group plc Provides Financial Guidance for the Year 2021

Upcoming dividend of UK£0.028 per share

Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)

Full year 2020 earnings released: EPS US$0.056 (vs US$0.005 in FY 2019)

Revenue beats expectations

Convatec Group Plc, Annual General Meeting, May 07, 2021

Convatec Group Plc to Report Fiscal Year 2020 Results on Mar 05, 2021

New 90-day low: UK£1.95

New 90-day high: UK£2.11

Convatec Group plc Revises Revenue Guidance for the Year 2020

Medline Industries, Inc. completed the acquisition of Aloe Vesta and SensiCare Skin Care Business of Convatec Group Plc (LSE:CTEC).

Convatec Group Plc announced that it has received funding from The Carlyle Group Inc.

Convatec Group Plc (LSE:CTEC) completed the acquisition of asset of Southlake Medical Supplies, Inc. for $12.3 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd